Home › Funds › ABLES, IANNONE, MOORE & ASSOCIATES, INC. › JNJ

ABLES, IANNONE, MOORE & ASSOCIATES, INC. position in JNJ

JOHNSON & JOHNSON · Health Care

ABLES, IANNONE, MOORE & ASSOCIATES, INC. reported holding 11,467 shares of JNJ (JOHNSON & JOHNSON) in its Q3 2026 13F filing — a position valued at US$3.0M, representing 1.57% of its reported portfolio and ranking #14 among its reported holdings. ABLES, IANNONE, MOORE & ASSOCIATES, INC. has disclosed JNJ holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)11.47K sh
Reported value held$3.04M
Portfolio Weight1.57%
First reportedQ4 2023
Last changeReduce
Updated2026-10-09

Last updated: 2026-10-09 · Source: SEC EDGAR Form 13F-HR

How ABLES, IANNONE, MOORE & ASSOCIATES, INC.'s JNJ position evolved

ABLES, IANNONE, MOORE & ASSOCIATES, INC. first disclosed a stake in JNJ in Q4 2023 at 14,674 shares (US$2.3M). The position peaked in Q3 2026 at 11,467 shares, worth US$3.0M. Across 12 filings, ABLES, IANNONE, MOORE & ASSOCIATES, INC. increased the stake 2 time(s), trimmed it 9 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 11,467 shares valued at US$3.0M — a reduction of -446 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q4 2023 14.67K $2.30M New
Q1 2024 14.37K $2.27M Reduce
Q2 2024 16.08K $2.35M Add
Q3 2024 15.95K $2.59M Reduce
Q4 2024 15.85K $2.29M Reduce
Q1 2025 15.48K $2.57M Reduce
Q2 2025 14.06K $2.15M Reduce
Q3 2025 12.51K $2.32M Reduce
Q4 2025 12.13K $2.51M Reduce
Q1 2026 11.46K $2.80M Reduce
Q2 2026 11.91K $3.03M Add
Q3 2026 11.47K $3.04M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About JNJ and 13F data

JNJ (JOHNSON & JOHNSON) is a Health Care company. 33 other funds we track also report a position in JNJ — the largest reported positions include BlackRock Inc (US$53.87B), Vanguard Group (US$49.74B), VANGUARD CAPITAL MANAGEMENT LLC (US$39.93B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding JNJ

All JNJ fund holders →

FAQ

How long has ABLES, IANNONE, MOORE & ASSOCIATES, INC. held JNJ?

ABLES, IANNONE, MOORE & ASSOCIATES, INC. has disclosed JNJ holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is ABLES, IANNONE, MOORE & ASSOCIATES, INC.'s current position in JNJ?

As of Q3 2026, ABLES, IANNONE, MOORE & ASSOCIATES, INC. holds 11.47K shares of JNJ (JOHNSON & JOHNSON), valued at $3.04M, representing 1.57% of its reported portfolio and ranking #14.

Has ABLES, IANNONE, MOORE & ASSOCIATES, INC. been buying or selling JNJ?

In the latest 13F filing (Q3 2026), ABLES, IANNONE, MOORE & ASSOCIATES, INC. reduced its position in JNJ. The position peaked in Q3 2026 at 11.47K shares.

Which other funds hold JNJ?

Other major institutional holders of JNJ include BlackRock Inc, Vanguard Group, VANGUARD CAPITAL MANAGEMENT LLC, among 33 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.